Recent developments for Pseudomonas vaccines

Hum Vaccin. 2011 Oct;7(10):999-1011. doi: 10.4161/hv.7.10.16369. Epub 2011 Oct 1.

Abstract

Infections with Pseudomonas aeruginosa are a major health problem for immune-compromised patients and individuals with cystic fibrosis. A vaccine against: P. aeruginosa has long been sought after, but is so far not available. Several vaccine candidates have been assessed in experimental animals and humans, which include sub-cellular fractions, capsule components, purified and recombinant proteins. Unique characteristics of the host and the pathogen have complicated the vaccine development. This review summarizes the current state of vaccine development for this ubiquitous pathogen, in particular to provide mucosal immunity against infections of the respiratory tract in susceptible individuals with cystic fibrosis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Biomedical Research / trends
  • Clinical Trials as Topic
  • Cystic Fibrosis / complications
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Humans
  • Immunity, Mucosal
  • Immunocompromised Host
  • Pseudomonas Infections / prevention & control*
  • Pseudomonas Vaccines / administration & dosage*
  • Pseudomonas Vaccines / immunology*
  • Pseudomonas aeruginosa / immunology*
  • Pseudomonas aeruginosa / pathogenicity*

Substances

  • Pseudomonas Vaccines